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We have come a long way in the past 50 years toward reducing death and disability from cardiovascular diseases (CVD) . And yet, as articulated by Wilmot KA et al. in this edition of
Circulation,
1 we still have a long way to go, especially for young women and some racial/ethnic groups. These new findings highlight the value of looking "behind the curtain" at health data, in particular teasing apart age-and sex-related outcomes.
Wilmot KA et al. now build on our understanding of CVD mortality by highlighting recent trends in sub-populations, including young women, and they are troubling. These investigators examined mortality data for U.S. men and women 25 years and older between 1979
and 2011 using U.S. National Vital Statistics data that focused on coronary heart disease (CHD). 1, 2 ICD-9 and ICD-10 codes were used to determine the underlying cause of CHD deaths.
Analyses of mortality data within three age groups (<55 years, 55 to 64 years, and 65+ years) during three decades (1979 to 1989, 1990 to 1999, and 2000 to 2011) yielded an initial assessment of mortality trends. Regression modeling then further evaluated trends in the estimated annual percentage change (EAPC) in CHD mortality across the entire time period, permitting calculation of statistically significant differences in EAPC from year to year.
On one hand, the news is good. The impressive (68 percent) decline in age-adjusted CHD mortality rate for both men and women across the overall study period is nothing short of remarkable and validates progressive improvements in CVD prevention and treatment. Overall, since 2002, older men and women (>age 65) continue to experience large reductions in CHD mortality, which drives this overall mortality decline.
Yet, disaggregating the data and recalculating mortality rates by age, gender, race, and time period points to worrisome new information. For both men and women, the EAPC was greater in older individuals (> 55 years) compared with those younger (<55 years). In addition, CHD). 1, 2 ICD-9 and ICD-10 codes were used to determine the underlying cause e o o of f f CH CH CHD D D de de deat at aths
Analyses of mortality data within three age groups (<55 years, 55 to 64 years, and 65+ years) duri ing ng ng t t thr hr hree ee ee d d decad ad ades e (1979 to 1989, 1990 to 1999 99 99, a a and 2000 to 2011) yi yi yiel e e ded an initial a a asse e essment of f mo mo mor rtal al lit it ity y tr tr tren en ends ds ds. Re Re Regr gr gres s ssi ion m m mo od o elin n ng the he hen n n fu fu furt r r he he h r r r ev ev eval al alu u uat ted tr tr tren en ends ds ds i i in n n th th the e e es s sti t t m m mated an n nnu n n al l l p p perce e en nt n age e ch h han a ge ge ge (EA EA EAPC C C) ) ) i in in CH HD D m m mo o orta a ality ty ty a a acr r ros s ss t t the e en n nti i ir r re tim m me e e pe eri i iod, pe pe perm rm rmit it itti ti ting ng ng c c cal al alcu c cula la lati ti tion on on o o of f f st st stat at atis is isti ti tica ca call ll lly si si sign gn gnif if ific ic ican an ant t t di di diff ff ffer er eren en ence ce ces s s in in in E E EAP AP APC C C fr fr from om om yea ea ear r r to to to yea ea ear r r.
men exhibited greater reductions in CHD mortality than did women when compared within age groups <65 years. For example, women <55 years had the lowest decline in CHD mortality. To that end, although the primary Framingham study population demographics yielded guidelines for prevention, diagnosis, and treatment targeted to an older-age group, many additional Framingham-style cohorts exist today and continue to provide data on subpopulations. NHLBI has been a leader in assembling an array of population studies focusing on ye e ear ar ars) s) s), with hou ou out si s m mi m lar r r a at a ten nt ti t on on on to o yo y y un un unge ge g r r pe pe people. Wo Wo Wom m men n n, i in n n p p par r rtic ic cul l lar r, ha ha have ve ve bee e en n n un n unde de derr rr rrep ep epre re rese se sent nt nted ed ed. Al Al Alth th thou o ough gh gh f f fed ed eder er eral al al r r reg eg egul l ulat at atio io ions ns ns i i in n n pl pl plac ac ace e e si si sinc nc nce e e 19 19 1993 93 93 h h hav a ave e e in in incr cr crea ea ease se sed d d th th the e e unique cohorts. These include the WHI, the Jackson Heart Study, Atherosclerosis Risk in Communities, the Multi-Ethnic Study of Atherosclerosis, the Strong Heart Study, and many more. 5 It will be important for these studies to disseminate their results broadly and to follow up on new hypotheses prompted by their ongoing investigations. Such findings may inform individualized care options for women and people of various ethnic/racial backgrounds, toward improving outcomes in these populations.
Third, many awareness and education programs that are indeed targeted to women, such as the Heart Truth campaign, Go Red for Women and Women Heart, were initially focused on older women. After several years of experience, however, this focus has shifted to younger women. Time will tell how effective these awareness programs are reaching their target audiences, but such activities must continue given the serious health situation at hand.
A fourth issue speaks to behavioral and cultural factors that shape human activities. Older individuals tend to seek more medical care and are more likely to be evaluated for CVD risk, compared to younger people. Additionally, compared to men, women at any age tend to be underdiagnosed and undertreated. Some of this is attributable to individual behaviors, but another element is the broader societal context in which women are often, still, the primary caretaker in a family, who may forego their own health needs for a variety of reasons.
Where do we go from here?
The data speaks to us loudly and clearly. Framingham risk scores for women ages 35 to 54 years with AMI have increased, likely due to a range of influences, some of which are mentioned above. These elevated Framingham scores in younger women provide a clarion call for prioritized research toward understanding the basis of worse risk factor profiles in this women. Time will tell how effective these awareness programs are reaching their r r ta ta targ rg rget et et audiences, but such activities must continue given the serious health situation at hand.
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Improving primary prevention strategies is a good place to start. Given the results reported in Wilmot et al., requiring CVD screening in women, and in men, over age 25 years seems warranted. Evidence should guide such prevention efforts, and data collectionaggregated by sex and age -should be ongoing to assess the value of screening on both quantitative and qualitative outcomes. Reaching young women relies on a group of health professionals: our primary care physicians, obstetricians, gynecologists, family practitioners, and other health providers who care for women routinely. Specialists, such as endocrinologists, can play an important role in CVD diagnosis and treatment by considering co-morbidities such as diabetes, which has risen dramatically in young women over the past few decades along with a concomitant increase in overweight and obesity. [6] [7] [8] [9] We should also continue to pursue novel CVD prevention and treatment modalities that are based on new mechanistic findings about CVD pathology. Over the past few years, it has become clear that PCSK9 monoclonal antibodies that lower blood LDL may offer some advantages over statins. 10 Continued basic research on the fundamental mechanisms of CVD at various life stages and in both sexes may offer additional valuable insights into new approaches that might be tailored specifically to individuals.
A common theme in the parlance of biomedicine today is that the era of personalized medicine is upon us. Beyond genomic and molecular foci, there is much more to consider.
Physicians have a responsibility to meet the needs of their patients on an individual level that is person-centric. Thus, personalized medicine addresses a patient's context, including the web of other health providers who care for women routinely. Specialists, such as endocrin in inol ol olog og ogis is ists ts ts, , , ca ca can n n play an important role in CVD diagnosis and treatment by considering co-morbidities such as diab bet et etes es es, , , wh wh whic i i h ha ha has s risen dramatically in young wo wo wom m men over the past fe fe ew w w decades along with a c co con nc ncomitant in incr cr crea ase e e i i in n n ov ov over er erwe we weig ig ight ht ht and n n obe be besit ty.
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It also employs communication strategies that meet people where they are: at work and at play, well beyond periodic health care visits. Communication to younger women through the wide range of social media outlets with which they interact frequently is an enormous opportunity to reach this group, who may not recognize vulnerability until it is validated by their peers.
Finally, the current seismic shifts in health care access and affordable preventive care have important implications for considering health in different populations, including women. In keeping with changes in health care that involve team care and that focus on prevention, enlisting the contributions of behavioral health specialists will go a long way toward both recognizing and mitigating CVD risk factors.
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